NGL Fine Chem Ltd Valuation Adjusts Amid Market Volatility

Valuation Metrics and Grade Revision

On 17 August 2026, NGL Fine Chem’s mojo grade was downgraded from Buy to Hold, reflecting a reassessment of its valuation standing. The company’s P/E ratio currently stands at 31.72, a decrease from previous levels that were categorised as very expensive. Similarly, the P/BV ratio is at 5.51, maintaining an expensive valuation status but indicating a slight easing compared to peer extremes. These valuation metrics, while still elevated relative to broader market averages, suggest that the stock’s price premium has moderated somewhat.

Other valuation multiples include an EV to EBIT of 29.54 and EV to EBITDA of 22.32, both consistent with an expensive profile but below the very expensive thresholds seen in some competitors. The PEG ratio remains low at 0.18, signalling that earnings growth expectations are still factored into the price, albeit with caution.

Comparative Industry Context

When benchmarked against peers within the Pharmaceuticals & Biotechnology sector, NGL Fine Chem’s valuation appears more reasonable, though still on the higher side. For instance, Ind-Swift Laboratories and Fredun Pharma are rated as very expensive with P/E ratios of 41.25 and 54.85 respectively, while Venus Remedies and Syncom Formulations trade at fair valuations with P/E ratios around 20.81 and 16.74. This positions NGL Fine Chem in the expensive category but not at the extreme end of the valuation spectrum.

EV to EBITDA multiples further reinforce this view, with NGL Fine Chem’s 22.32 ratio below Ind-Swift’s 38.56 and Fredun Pharma’s 23.15, but above Venus Remedies’ 14.01 and Syncom Formulations’ 15.03. The company’s PEG ratio of 0.18 is notably lower than many peers, suggesting that despite the high absolute valuation, growth expectations remain relatively attractive.

Price Performance and Market Capitalisation

NGL Fine Chem’s current market price is ₹2,937.00, down 15.18% on the day from a previous close of ₹3,462.60. The stock’s 52-week high is ₹3,595.00, while the low stands at ₹1,261.00, indicating significant volatility over the past year. Despite the recent sharp decline, the stock has delivered a remarkable 112.09% return over the last 12 months, substantially outperforming the Sensex’s 3.56% loss in the same period.

However, shorter-term returns have been less favourable, with a one-week decline of 15.23% compared to the Sensex’s modest 1.04% drop, and a one-month loss of 6.21% versus the benchmark’s 0.54% fall. This divergence highlights the stock’s sensitivity to market sentiment and valuation concerns.

Profitability and Efficiency Metrics

From a profitability standpoint, NGL Fine Chem demonstrates solid operational efficiency. The latest return on capital employed (ROCE) is 13.29%, while return on equity (ROE) stands at 14.59%. These figures indicate effective utilisation of capital and shareholder funds, supporting the company’s growth narrative despite valuation pressures.

Dividend yield data is not available, which may be a consideration for income-focused investors. The company’s EV to capital employed ratio of 4.78 and EV to sales of 3.50 further reflect its capital structure and revenue generation efficiency relative to enterprise value.

Historical Returns and Long-Term Outlook

Examining longer-term returns, NGL Fine Chem has delivered a staggering 743.24% gain over the past decade, vastly outperforming the Sensex’s 177.55% rise. This exceptional performance underscores the company’s ability to generate shareholder value over extended periods, albeit with periods of volatility and valuation adjustments.

Over five years, however, the stock has declined by 9.19%, contrasting with the Sensex’s 39.32% gain, suggesting some cyclical or sector-specific headwinds impacting medium-term performance. The three-year return of 49.11% still outpaces the Sensex’s 19.30%, indicating a recovery phase and renewed investor interest.

Implications for Investors

The downgrade from Buy to Hold reflects a cautious stance on NGL Fine Chem’s valuation, which, while less stretched than before, remains elevated relative to many peers and the broader market. Investors should weigh the company’s strong historical returns and solid profitability against the recent price correction and valuation moderation.

Given the stock’s micro-cap status and sector-specific risks, including regulatory and competitive pressures in Pharmaceuticals & Biotechnology, a Hold rating suggests monitoring for further clarity on earnings momentum and valuation stability before committing additional capital.

Moreover, the company’s PEG ratio of 0.18 indicates that growth expectations are still priced in, but any earnings disappointments could exacerbate downside risks. Conversely, the attractive long-term returns and robust ROCE and ROE metrics provide a foundation for potential recovery if market conditions improve.

Conclusion

NGL Fine Chem Ltd’s recent valuation shift from very expensive to expensive signals a recalibration of investor sentiment amid volatile market conditions. While the stock’s fundamentals remain solid, the downgrade to a Hold mojo grade underscores the need for prudence given the current price correction and elevated multiples. Investors should continue to monitor the company’s financial performance and sector dynamics closely, balancing the potential for long-term gains against near-term valuation risks.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →